Business Description
Centessa Pharmaceuticals PLC
Share Class Description:
LTS:0ACX: ADRDescription
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.12 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.58 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 10.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -128.1 | |||||
| 3-Year EPS without NRI Growth Rate | -118.7 | |||||
| 3-Year FCF Growth Rate | -123.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.04 | |||||
| 9-Day RSI | 51.69 | |||||
| 14-Day RSI | 52.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 21.52 | |||||
| Quick Ratio | 21.52 | |||||
| Cash Ratio | 19.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.8 | |||||
| Shareholder Yield % | -15.81 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2358.87 | |||||
| Net Margin % | -2353.2 | |||||
| FCF Margin % | -1901.84 | |||||
| ROE % | -53.87 | |||||
| ROA % | -38.87 | |||||
| ROIC % | -240.17 | |||||
| ROC (Joel Greenblatt) % | -1170.74 | |||||
| ROCE % | -38.59 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 236.64 | |||||
| PB Ratio | 4.37 | |||||
| Price-to-Tangible-Book | 4.37 | |||||
| EV-to-EBIT | -12.11 | |||||
| EV-to-EBITDA | -12.2 | |||||
| EV-to-Revenue | 261.85 | |||||
| EV-to-FCF | -14.41 | |||||
| Price-to-Net-Current-Asset-Value | 4.76 | |||||
| Price-to-Net-Cash | 5.34 | |||||
| Earnings Yield (Greenblatt) % | -8.26 | |||||
| FCF Yield % | -5.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Centessa Pharmaceuticals PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.853 | ||
| EPS (TTM) ($) | -1.52 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 52.18 | ||
| 14-Day ATR ($) | 0.790575 | ||
| 20-Day SMA ($) | 17.338457 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 8.49 - 18.8611 | ||
| Shares Outstanding (Mil) | 131.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Centessa Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Centessa Pharmaceuticals PLC Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Centessa Pharmaceuticals PLC Frequently Asked Questions
What is Centessa Pharmaceuticals PLC(LTS:0ACX)'s stock price today?
The current price of LTS:0ACX is $16.57. The 52 week high of LTS:0ACX is $18.86 and 52 week low is $8.49.
When is next earnings date of Centessa Pharmaceuticals PLC(LTS:0ACX)?
The next earnings date of Centessa Pharmaceuticals PLC(LTS:0ACX) is 2025-03-28 Est..
Does Centessa Pharmaceuticals PLC(LTS:0ACX) pay dividends? If so, how much?
Centessa Pharmaceuticals PLC(LTS:0ACX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers